Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan, Platinum, Tislelizumab, and Anlotinib for ES-SCLC
NCT06951841Phase 4Not yet recruiting
- Sponsor
- China Medical University
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome injection in small cell lung cancer (SCLC), sponsored by China Medical University. Primary endpoint: Progression-free survival at 6 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06951841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951841.